Puma Biotechnology Company Profile (NYSE:PBYI)

About Puma Biotechnology (NYSE:PBYI)

Puma Biotechnology logoPuma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NYSE:PBYI
  • CUSIP: N/A
  • Web: www.pumabiotechnology.com/
Capitalization:
  • Market Cap: $4.64 billion
  • Outstanding Shares: 37,205,000
Average Prices:
  • 50 Day Moving Avg: $112.81
  • 200 Day Moving Avg: $79.93
  • 52 Week Range: $28.35 - $127.02
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -26.58
  • P/E Growth: 0.03
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.24 per share
  • Price / Book: 38.47
Profitability:
  • EBITDA: ($289,010,000.00)
  • Return on Equity: -217.17%
  • Return on Assets: -160.32%
Debt:
  • Current Ratio: 3.12%
  • Quick Ratio: 3.12%
Misc:
  • Average Volume: 818,798 shs.
  • Beta: 0.35
  • Short Ratio: 6.75
 

Frequently Asked Questions for Puma Biotechnology (NYSE:PBYI)

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NYSE:PBYI) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($2.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.32) by $0.78. View Puma Biotechnology's Earnings History.

When will Puma Biotechnology make its next earnings announcement?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Puma Biotechnology.

Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?

9 equities research analysts have issued 12-month target prices for Puma Biotechnology's shares. Their forecasts range from $88.00 to $156.00. On average, they anticipate Puma Biotechnology's share price to reach $124.89 in the next year. View Analyst Ratings for Puma Biotechnology.

Who are some of Puma Biotechnology's key competitors?

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:

  • Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer
  • Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer
  • Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer
  • Steven Lo, Chief Commercial Officer
  • Jay M. Moyes, Independent Director
  • Adrian M. Senderowicz M.D., Independent Director
  • Troy E. Wilson Ph.D. J.D., Independent Director
  • Frank E. Zavrl, Independent Director

Who owns Puma Biotechnology stock?

Puma Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.04%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.

Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?

Puma Biotechnology's stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. View Insider Buying and Selling for Puma Biotechnology.

How do I buy Puma Biotechnology stock?

Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of Puma Biotechnology stock can currently be purchased for approximately $124.65.


MarketBeat Community Rating for Puma Biotechnology (NYSE PBYI)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  295 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  502
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Puma Biotechnology (NYSE:PBYI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $124.89 (0.19% upside)
Consensus Price Target History for Puma Biotechnology (NYSE:PBYI)
Price Target History for Puma Biotechnology (NYSE:PBYI)
Analysts' Ratings History for Puma Biotechnology (NYSE:PBYI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Bank of America CorporationReiterated RatingBuy$117.00 -> $135.00N/AView Rating Details
10/5/2017Citigroup Inc.Reiterated RatingBuy$114.00 -> $156.00N/AView Rating Details
10/4/2017J P Morgan Chase & CoReiterated RatingBuy$131.00HighView Rating Details
10/2/2017Stifel NicolausBoost Price TargetBuy$110.00 -> $130.00LowView Rating Details
9/27/2017Credit Suisse GroupReiterated RatingOutperform$136.00HighView Rating Details
9/6/2017Barclays PLCInitiated CoverageOverweight$103.00HighView Rating Details
8/2/2017Leerink SwannReiterated RatingOutperform$125.00LowView Rating Details
7/22/2017Cowen and CompanyReiterated RatingOutperform$91.00 -> $120.00MediumView Rating Details
7/17/2017Royal Bank Of CanadaSet Price TargetHold$88.00MediumView Rating Details
1/5/2016Berenberg BankUpgradeHold -> BuyN/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Puma Biotechnology (NYSE:PBYI)
Earnings by Quarter for Puma Biotechnology (NYSE:PBYI)
Earnings History by Quarter for Puma Biotechnology (NYSE PBYI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($2.50)N/AView Earnings Details
8/9/2017Q2 2017($1.32)($2.10)ViewN/AView Earnings Details
5/10/2017Q1 2017($2.06)($1.97)ViewN/AView Earnings Details
3/1/2017Q4($1.92)($2.04)ViewN/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Puma Biotechnology (NYSE:PBYI)
Current Year EPS Consensus Estimate: $-8.69 EPS
Next Year EPS Consensus Estimate: $-4.69 EPS

Dividends

Dividend History for Puma Biotechnology (NYSE:PBYI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Puma Biotechnology (NYSE:PBYI)
Insider Ownership Percentage: 22.70%
Institutional Ownership Percentage: 80.98%
Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)
Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)
Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/29/2017Richard Paul BryceSVPSell15,000$120.00$1,800,000.00View SEC Filing  
9/7/2017Richard Paul BryceSVPSell15,000$100.09$1,501,350.00View SEC Filing  
7/20/2017Alan H AuerbachInsiderSell13,175$94.73$1,248,067.75View SEC Filing  
7/20/2017Richard Paul BryceSVPSell1,998$94.48$188,771.04View SEC Filing  
7/3/2017Richard Paul BryceSVPSell5,000$87.10$435,500.00View SEC Filing  
6/12/2017Adage Capital Partners Gp, L.LMajor ShareholderSell247,260$80.32$19,859,923.20View SEC Filing  
6/5/2017Adage Capital Partners Gp, L.LMajor ShareholderSell507,128$87.84$44,546,123.52View SEC Filing  
5/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,235,700$75.38$93,147,066.00View SEC Filing  
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.64View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.48View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.32View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Puma Biotechnology (NYSE:PBYI)
Latest Headlines for Puma Biotechnology (NYSE:PBYI)
Source:
Loading headlines, please wait.

Social

Chart

Puma Biotechnology (PBYI) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.